Cyclovirobuxine D inhibits growth and progression of non-small cell lung cancer cells by suppressing the KIF11-CDC25C-CDK1-CyclinB1 G(2)/M phase transition regulatory network and the NFκB/JNK signaling pathway

Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common pathological subtype of lung cancer and is associated with low 5-year overall survival rates. Therefore, novel and effective chemotherapeutic drugs are urgently required for...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Ting, Chen, Yaodong, Xu, Jia, Du, Weiqin, Kong, Pengzhou, Zhang, Xinri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124714/
https://www.ncbi.nlm.nih.gov/pubmed/36929198
http://dx.doi.org/10.3892/ijo.2023.5505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124714/
https://www.ncbi.nlm.nih.gov/pubmed/36929198
http://dx.doi.org/10.3892/ijo.2023.5505

Ejemplares similares